Clinical Research Directory
Browse clinical research sites, groups, and studies.
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Sponsor: Institute of Tropical Medicine, Belgium
Summary
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking. In this study, longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics. This data will be crucial to provide more information on duration and dosing of miltefosine in CL patients globally, and in Ethiopia and pediatric patients in particular.
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2024-06-18
Completion Date
2026-12-30
Last Updated
2024-07-23
Healthy Volunteers
Not specified
Conditions
Interventions
Miltefosine
Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
Locations (1)
Africa Leprosy, Tuberculosis, Rehabilitation and Training (ALERT) Hospital
Addis Ababa, Ethiopia